Columbia Care

Columbia Care earns a Neutral rating, with a composite score of 49.8 and low conviction at 1/5. Fundamentals provide the principal support at 66.0, well ahead of the regulatory pillar at 49.0, market pillar at 40.0, and editorial pillar at 30.0. The fundamentals result reflects comparatively stronger gross-margin, operating-margin, market-cap-tier, and cash-runway subscores, although the stretched financial condition limits the rating. Regulatory performance remains mixed, pairing a neutral jurisdiction posture with weak filing cadence and no enforcement hits. The market contribution is constrained by unavailable institutional pricing, while the editorial contribution reflects no recent CIN newsroom coverage or briefs.

Licensed fundamentals data show year-over-year revenue slipping by roughly 0.3%, leaving the revenue-growth subscore near 50 and providing no top-line momentum. Gross margin was approximately 39.3%, supporting a 65.6 subscore, while the negative 9.2% operating margin nonetheless produced the strongest margin-related subscore at 69.8. EBITDA was positive at about $25.8 million, but net income remained a loss of roughly $401.8 million. That divergence produced a high cash-runway subscore without changing the stretched financial condition; positive EBITDA does not offset the scale of the bottom-line loss. Market capitalization of about $521.3 million supported the 68.7 market-cap-tier subscore. Primary regulatory filings show no dated latest filing and no recorded events across either the 90-day or 180-day windows, driving the cadence subscore to 25. Institutional pricing feeds provide no available quote, and CIN newsroom coverage records no recent newsroom or brief activity.

The clearest forward catalyst sits within fundamentals, the strongest pillar. A return to positive revenue growth, combined with preservation of the roughly 39% gross margin and improvement from the negative operating margin, would strengthen the weakest operating element while reinforcing the existing margin and EBITDA support. Better filing cadence could lift regulatory scoring, but it carries less rating leverage than measurable operating improvement. Market and editorial scores could recover with renewed pricing availability and coverage, yet neither addresses the stretched financial profile. The single most important signal to watch is a sustained return to positive year-over-year revenue growth alongside a narrowing operating loss.